The 11 analysts offering 12-month price forecasts for Arrowhead Pharmaceuticals Inc have a median target of 81.00, with a high estimate of 98.00 and a low estimate of 34.00. The median estimate represents a +28.61% increase from the last price of 62.98.
The current consensus among 11 polled investment analysts is to Buy stock in Arrowhead Pharmaceuticals Inc. This rating has held steady since November, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.18
Reporting Date Feb 10
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.